Table 2. Clinico-pathological association of SOX9 immunostaining in all cancers.

Parameter	Evaluable (n)	SOX9 (%)				P value
		negative	weak	moderate	strong
Total	7565	33	15	39	13
Tumor stage						<0.0001
pT2	4921	32	14	40	15
pT3a	1725	34	18	37	11
pT3b	848	34	20	36	10
pT4	40	43	25	28	5
Gleason grade						<0.0001
≤3+3	1741	38	11	37	14
3+4	4363	30	16	40	14
4+3	1115	34	20	36	10
≥4+4	306	38	19	32	11
Lymph node metastasis						0.04
N0	4233	32	17	39	13
N+	371	36	18	37	9
Preoperative PSA level (ng/ml)						<0.0001
<4	905	25	14	43	18
4–10	4597	31	15	41	14
>10–20	1487	37	18	33	12
>20	491	48	17	29	6
Surgical margin						0.01
negative	6053	32	15	39	14
positive	1374	37	16	36	12